Systemic Sclerosis (Scleroderma)

Last updated: March 16, 2026Bookmark

Systemic sclerosis is a chronic autoimmune connective tissue disease characterised by skin fibrosis (scleroderma), fibrosis of the internal organs, vasculopathy, and immune system dysregulation.

It is more common in women and peaks between 60 and 70 years.

Classification

ClassificationDescription
Limited cutaneous systemic sclerosisThis involves a large area of the body. Anti-topoisomerase (Scl-70) and anti-RNA polymerase antibodies may be present. Internal organ involvement is more severe with a higher risk of renal crisis, interstitial lung disease, and cardiac involvement. Its prognosis is poor.
Diffuse cutaneous systemic sclerosisThis involves a large area of the body. Anti-topoisomerase (Scl-70) and anti-RNA polymerase antibodies may be present. Internal organ involvement is more severe with a higher risk of renal crisis, interstitial lung disease and cardiac involvement. Its prognosis is poor.
  • Pathophsyiology
    • Autoantibody and cytokine production → chronic inflammation → activation of fibroblasts and differentiation into myofibroblasts → excessive deposition of extracellular matrix components in the skin and internal organs → fibrosis and organ dysfunction
    • Endothelial injury → vascular dysfunction → vasospasms and obliteration of vascular lumen → hypertension, pulmonary arterial hypertension, Raynaud’s phenomenon, and digital ulcers
  • Signs and symptoms
    • Skin fibrosis
      • Thickening, tightening, and hardening
      • Starts distally and progresses proximally
    • Raynaud’s phenomenon
    • Dysphagia
    • Gastroesophageal reflux
    • Motility disorders affecting the esophagus, stomach, and intestines
    • Interstitial lung disease and pulmonary hypertension
      • Shortness of breath
      • Cough
      • Chest pain
    • Hypertension
    • Renal failure
    • Joint pain and stiffness
    • Contractures due to fibrosis of the joint capsules and tendons
  • Physical examination
    • Abnormal capillary patterns on nailfold capillaroscopy
      • Dilatation
      • Avascular areas
      • Neangiogenesis
  • Differentials
  • Investigations
    • Anti-topoisomerase I (Scl-70) positive for diffuse cutaneous systemic sclerosis
    • Anti-centromere positive for limited cutaneous systemic sclerosis
    • Anti-RNA polymerase III positive
    • High-res CT scan for interstitial lung disease
    • Echocardiography for pulmonary hypertension
    • Skin biopsy
      • Dermal fibrosis and collagen deposition
  • Treatment
    • No cure currently exists
    • Physiotherapy and occupational therapy
    • Psychological support
    • Strict blood pressure control
    • Monitor renal function
    • Regular ACEi or ARBs to reduce the risk of renal crisis
    • CCBs, phosphodiesterase-5 inhibitors, and prostacycline analogues for Raynaud’s phenomenon, digital ulcers, and pulmonary hypertension
    • Immunosuppressants for organ involvement or rapidly progressive skin disease
    • PPIs and prokinetic agents for GERD and motility disorders
    • Antifibrotic tyrosine kinase
  • Complications
    • Interstitial lung disease
    • Pulmonary arterial hypertension (PAH)
    • Scleroderma renal crisis
    • Myocardial fibrosis
    • Arrhythmia
    • Heart failure
    • Gastroparesis
    • Intestinal pseudo-obstruction
  • Prognsis
    • 10-year survival rate over 70%. This varies based on multiple prognostic factors.
Reference Intervals
Biochemistry
ACTHP: <80 ng/L
ALTP: 5–35 U/L
AlbuminP: 35–50 g/L
AldosteroneP: 100–500 pmol/L
Alk. phosphataseP: 30–130 U/L
α-AmylaseP: 0–180 IU/dL
α-FetoproteinS: <10 kU/L
Angiotensin IIP: 5–35 pmol/L
ADHP: 0.9–4.6 pmol/L
ASTP: 5–35 U/L
BicarbonateP: 24–30 mmol/L
BilirubinP: 3–17 μmol/L
BNPP: <50 ng/L
CRPP: <10 mg/L
CalcitoninP: <0.1 mcg/L
Calcium (ionized)P: 1.0–1.25 mmol/L
Calcium (total)P: 2.12–2.60 mmol/L
ChlorideP: 95–105 mmol/L
CholesterolP: <5.0 mmol/L
VLDLP: 0.128–0.645 mmol/L
LDLP: <2.0 mmol/L
HDLP: 0.9–1.93 mmol/L
Cortisol AMP: 450–700 nmol/L
Cortisol MidnightP: 80–280 nmol/L
CK ♂P: 25–195 U/L
CK ♀P: 25–170 U/L
CreatinineP: 70–100 μmol/L
FerritinP: 12–200 mcg/L
FolateS: 2.1 mcg/L
FSHP: 2–8 U/L ♂; >25 menopause
GGT ♂P: 11–51 U/L
GGT ♀P: 7–33 U/L
Glucose (fasting)P: 3.5–5.5 mmol/L
Growth hormoneP: <20 mu/L
HbA1C (DCCT)B: 4–6%
HbA1C (IFCC)B: 20–42 mmol/mol
Iron ♂S: 14–31 μmol/L
Iron ♀S: 11–30 μmol/L
Lactate (venous)P: 0.6–2.4 mmol/L
Lactate (arterial)P: 0.6–1.8 mmol/L
LDHP: 70–250 U/L
LHP: 3–16 U/L
MagnesiumP: 0.75–1.05 mmol/L
OsmolalityP: 278–305 mosmol/kg
PTHP: 0.8–8.5 pmol/L
PotassiumP: 3.5–5.3 mmol/L
Prolactin ♂P: <450 U/L
Prolactin ♀P: <600 U/L
PSAP: 0–4 mcg/mL
Protein (total)P: 60–80 g/L
Red cell folateB: 0.36–1.44 μmol/L
Renin (erect)P: 2.8–4.5 pmol/mL/h
Renin (recumbent)P: 1.1–2.7 pmol/mL/h
SodiumP: 135–145 mmol/L
TBGP: 7–17 mg/L
TSHP: 0.5–4.2 mU/L
T4P: 70–140 nmol/L
Free T4P: 9–22 pmol/L
TIBCS: 54–75 μmol/L
TriglyceridesP: 0.50–2.3 mmol/L
T3P: 1.2–3.0 nmol/L
Troponin TP: <0.1 mcg/L
Urate ♂P: 210–480 μmol/L
Urate ♀P: 150–390 μmol/L
UreaP: 2.5–6.7 mmol/L
Vitamin B12S: 0.13–0.68 nmol/L
Vitamin DS: 50 nmol/L
Arterial Blood Gases
pH7.35–7.45
PaCO₂4.7–6.0 kPa
PaO₂>10.6 kPa
Base excess±2 mmol/L
Urine
Cortisol (free)<280 nmol/24h
Hydroxyindole acetic acid16–73 μmol/24h
Hydroxymethylmandelic acid16–48 μmol/24h
Metanephrines0.03–0.69 μmol/mmol cr.
Osmolality350–1000 mosmol/kg
17-Oxogenic steroids ♂28–30 μmol/24h
17-Oxogenic steroids ♀21–66 μmol/24h
17-Oxosteroids ♂17–76 μmol/24h
17-Oxosteroids ♀14–59 μmol/24h
Phosphate (inorganic)15–50 mmol/24h
Potassium14–120 mmol/24h
Protein<150 mg/24h
Protein/creatinine ratio<3 mg/mmol
Sodium100–250 mmol/24h
Haematology
WCC4.0–11.0 ×10⁹/L
RBC ♂4.5–6.5 ×10¹²/L
RBC ♀3.9–5.6 ×10¹²/L
Hb ♂130–180 g/L
Hb ♀115–160 g/L
PCV ♂0.4–0.54 L/L
PCV ♀0.37–0.47 L/L
MCV76–96 fL
MCH27–32 pg
MCHC300–360 g/L
RDW11.6–14.6%
Neutrophils2.0–7.5 ×10⁹/L (40–75%)
Lymphocytes1.0–4.5 ×10⁹/L (20–45%)
Eosinophils0.04–0.44 ×10⁹/L (1–6%)
Basophils0–0.10 ×10⁹/L (0–1%)
Monocytes0.2–0.8 ×10⁹/L (2–10%)
Platelets150–400 ×10⁹/L
Reticulocytes0.8–2.0% / 25–100 ×10⁹/L
Prothrombin time10–14 s
APTT35–45 s
Paediatric
Pulse Rate (bpm)
Neonate140–160
Infant <1yr120–140
1–5 years110–130
5–12 years80–120
>12 years70–100
Respiratory Rate (tachypnoea)
0–2 months≥60/min
2–12 months≥50/min
1–5 years≥40/min
>5 years≥30/min
Blood Pressure (mmHg)
Term65/45
1 year75/50
4 years85/60
8 years95/65
10 years100/70
Weight Formulas
3–12 months(a + 9)/2 kg
1–6 years2a + 8 kg
>6 years(7a − 5)/2 kg
Haemoglobin (g/dL)
Term newborn13–20
1 month11–18
2 months10–15
1–2 years10–13
>2 years11–14
MUAC (6 months–5 years)
Obese>17.5 cm
Normal13.5–17.4 cm
At risk12.5–13.4 cm
Moderate malnutrition11.5–12.4 cm
Severe malnutrition<11.5 cm
Developmental Milestones
Social smile1.5 months
Head control4 months
Sits unsupported7 months
Crawls10 months
Stands unsupported10–12 months
Walks12–13 months
Talks18 months
CSF WBC (/mm³)
Term newborn0–25
>2 weeks0–5
Calculator

Leave a Reply

Your email address will not be published. Required fields are marked *

A moment of your time
Step 1 of 2

You are the reason this exists. Got 60 seconds? Help us improve Hyperexcision for every medical student who uses it.

The Hyperexcision Team